Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease?

Brain. 2015 Apr;138(Pt 4):829-30. doi: 10.1093/brain/awu407. Epub 2015 Feb 10.

Authors

Erwan Bezard¹, Manolo Carta²

Affiliations

¹ 1 Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France 2 CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France erwan.bezard@u-bordeaux.fr.
² 3 Department of Biomedical Sciences, Section of Physiology, University of Cagliari, University Campus, SS554 km 4.5, 09042 Monserrato, Italy.

PMID: 25669729
DOI: 10.1093/brain/awu407

No abstract available

Publication types

Comment

MeSH terms

Dyskinesia, Drug-Induced / drug therapy*
Female
Humans
Levodopa / adverse effects*
Male
Parkinson Disease / drug therapy*
Piperazines / therapeutic use*

Substances

Piperazines
Levodopa
eltoprazine